TERMS AND CONDITIONS
GHAGA awards Terms and Conditions
These terms and conditions (the "T&Cs") are intended to govern the operation of the Grifols Hemophilia Awareness Global Awards (the "GHAGA awards") organized by Grifols, S.A., a company duly incorporated under Spanish law, with Tax ID number A-58389123 and with registered offices at calle Jesús y María 6, 08022 Barcelona – Spain ("Grifols").
GHAGA awards aim at improving the standards and benefits for the patient care in hemophilia where it is not yet or not easily available.
These T&Cs are available for consultation on www.grifols.com (the "Website").
Participation in the GHAGA awards is voluntary and free of charge. Participants may be healthcare providers, hemophilia treatment centers as well as hemophilic societies that contribute to improve the quality of life of hemophilia patients.
The participants in the GHAGA awards may present their proposal individually or as part of a team. Both individual participants' and team participants will be jointly referred to as the "Participants".
Participants shall meet the following eligibility requirements:
- present an innovative proposal that fulfills the program objectives as set out in Section 4.1 below and constitutes a focused project with goals that can be achieved within a maximum of 18 months;
- be a healthcare organization, such as hospitals, universities or independent institutions (the "Institution"), or be a healthcare provider (including without limitation doctors, nurses, scientists, pharmacists or physical therapists) ("HCP");
- who is(are) developing a project in the field of hemophilia, and
- Participants who are an HCP must be employed and / or explicitly supported by an Institution.
None of Grifols' and/or its group companies' personnel or any relative up to the second degree of kinship of the persons directly involved in the management of Grifols' awards or in the awardee selection process shall be eligible to participate in the GHAGA awards.
Unless expressly stated in these T&Cs, in no case shall Grifols bear any costs and/or expenses in which the participants may incur by reason of their participation in the GHAGA awards.
3. Period of participation and timeline
The period of participation for the GHAGA awards will commence on 6th July 2019 and will finish on 31st December 2019.
(a) Submission, in ENGLISH, of the following dossier (the Dossier):
- A brief resume or CV of the HCP
- A brief description of the Institution either as applicant, or as employer and supporter of participants who are HCPs
- In case of HCPs, a letter of authorization from the Institution expressly authorizing the HCPs to submit a proposal in relation with a project to the selection process of the GHAGA awards
- The project (background, objectives, design and contribution to quality of life improvement)
- The timelines and budget analysis
- Complete Application Form and Letter of Intent, as each accessible on the Website.
(b) Upon receipt of the Dossiers, selection by the Review Committee (as such term is defined in Section 4 below) of the participants admitted to submit a full proposal; such Participants will receive additional questions and / or an additional questionnaire to be completed;
(c) Submission of the additional questionnaires and / or questions, as completed by the participants selected under paragraph b) above;
(d) Selection by the Review Committee of the full proposals awarded in each of the four categories defined in Section 4.1 (a)
(e) Announcement by Grifols of the awards to each of the awardees and announcement on the website;
(f) The awards ceremony will be held during the World Federation of Hemophilia (WFH) World Congress 2020 that will take place in Kuala Lumpur (Malaysia) from 14th to 17th June 2020 (the "Awards Ceremony").
PLEASE KINDLY NOTE: Only complete Dossiers will be further assessed in the selection process for the GHAGA awards. At each step, the proposals of the participants, which Dossiers do not meet the eligibility or other requirements, will be disqualified and will not be considered for the rest of the awardees selection process.
4. Awards details
Applicants (either individual participants or the participants in a team designated to present the proposal (the "Proposal") should complete their Dossier and submit it following the terms set forth in Section 3.
Once the period to submit the Application Form ends an independent jury formed by a panel of leading experts in clinical and academic medicine, whose identity details are published on the Website (the "Review Committee"), shall select:
(i) In a first step, among the participants having submitted a Dossier, the participants admitted to submit a full proposal; as Grifols is fully committed to adhering to the highest integrity and ethical standards, and expects the same of any person with whom interactions are established, Grifols will request the participants admitted to submit a full proposal, to complete an additional questionnaire, as a condition for further consideration of their proposal in the awardees' selection process;
(ii) In a second step, among the participants having submitted a full proposal, the four (4) participants' projects (as such term is defined below) that best match the objectives of the program detailed in Section 4.1, taking into consideration the appraisal criteria described in Section 4.2 (the "Awardees").
Only participants fulfilling all of the above requirements and criteria will be considered to be selected as awardees. The awardees will be required to enter into a contract with the Institution and Grifols (the "Contract") which will set out the terms and conditions upon which the prize for the project will be granted to the Institutions employing or supporting the awardees.
The awardees will be announced on the Website with their name, last name, photo, job position, designation of work place, biography and title and summary of the project.
The awardees are required to attend the Awards Ceremony in order to be awarded. Any costs and/or expenses associated with the attendance of the awardees to the Awards Ceremony will be borne by Grifols or, if these have been already paid by the awardees or the awardees' Institution, the Awardees or the Awardees' Institution shall be reimbursed by Grifols upon Grifols being provided with evidence of the costs and/or expenses incurred and subject, in any event, to any applicable local laws and regulations.
Participants shall provide all information requested in the course of the selection process in English using the form or documents provided by Grifols, when they are made available.
4.1 Requirements of the Projects
Participants must present an innovative project that contributes to improve the quality of life of hemophilia patients and that permits complying with the following requirements (the "Project"):
(a) Program objectives
(i) Outreach diagnosis by increasing disease awareness or access to diagnosis (endorse reference centers to work on better logistics or facilities, support national or local registries, help to develop hemophilia treatment centers processes);
(ii) Improve education to patients, families, caregivers, healthcare providers or patients advocacy groups (educational stages in other centers, workshops, pathology training and programs to educate patients and families);
(iii) Strengthen diagnosis (help to improve patients care and quality control in hemophilia centers) ; or
(iv) Facilitate access to treatment (Support patient or family travels, improve in logistics organization).
(b) Project goals should be achieved within a maximum of eighteen (18) months from the date of the first payment agreed in the Contract, in case participants become selected as awardees.
(c) In no case, submitted Projects shall include any information or data which allows, directly or indirectly, the identification of any individual who is not a member of the participant's team and/or the Institution;
In case participants become selected as awardees, they agree to provide Grifols with an interim report (which shall include a financial report of the fund and any other project realization evidence) within twelve (12) months from the date of the first payment agreed in the Contract (the "Interim Report") and a full report after completion of the project (the "Final Report"). Eventually, the project description and realization will be used for its publication in reports, newsletters and media releases related to the GHAGA awards news.
4.2 Appraisal criteria
The projects will be assessed by the Review Committee taking into account the following criteria:
(a) Scientific merit, which will take into account (i) the validity of the expected outcomes, (ii) the validity of its potential regional impact, and (iii) the feasibility of completing the proposed work within a maximum term of eighteen (18) months from the date of the first payment agreed in the contract, in case participants become selected as awardees;
(b) Clinical/medical impact, which will take into account (i) the validity of the rationale/expected outcomes to contribute to increase disease awareness and/or access to diagnosis, offer education or improve patient care, and (ii) proposals showing potential regional impact (which will be highly evaluated), and
(c) Plan execution and grant awardees, which will take into account (i) qualification of each participant and of the Institution supporting the participant, (ii) expertise in the area where the proposal will be executed, and (iii) profile of the participant.
Each of the four (4) selected projects will be awarded with an amount of Euros 50,000 (the "Awards"). The payment of the awards will be made by Grifols to the Awardee's Institution with the following payment schedule and subject, if applicable, to holding a certificate of residents for non-Spanish residents:
- Thirty-five thousand Euros (€35,000) (gross amount) within sixty (60) days from the signature date of the Contract (the "First Installment").
- Ten thousand Euros (€10,000) (gross amount) within sixty (60) days of receipt by Grifols of the Interim Report (the "Second Installment").
- Five thousand Euros (€5,000) (gross amount) within sixty (60) days of receipt by Grifols of the Final Report (the "Third Installment").
The awardee(s) acknowledges that Grifols will not transfer any payment of the awards directly to him/her/them.
6. Representations and Warranties. Intellectual and Industrial Property
The participants represent and warrant that (a) they are the authors responsible for the submitted project, (b) the Dossier, the proposal, any submitted documents and/or information provided are accurate and updated, (c) the project is an original creation, (d) they have obtained all necessary approvals from the Institution to participate in the GHAGA awards and their participation do not violate any duty owed to the Institution or any other third party, (e) the project complies with all applicable health regulations, and (f) their participation in the GHAGA awards and the exercise by Grifols of the rights licensed herein does not infringe any legal provisions, agreements, rights or assets owned by any third party.
The Institution will be the exclusive owner of the economic rights of intellectual and industrial property over the project. By participating in the GHAGA awards, Grifols is granted a worldwide, non-exclusive, non-transferable (except to Grifols' group companies) royalty free license to use any and all results derived, directly or indirectly, from the project for Grifols' internal research and development purposes. The awardee shall present any information, data and/or results derived from the project only with the prior written consent of Grifols, which consent shall not be unreasonably withheld.
7. Data Protection
8. Applicable Law and Jurisdiction
These T&Cs are governed by Spanish law.
If any disputes arise from the interpretation and/or execution of the provisions regulated in these T&Cs, the parties will try to resolve these disputes amicably. If the dispute, controversy or difference cannot be amicably resolved, the parties shall submit the dispute, controversy or difference exclusively to the courts of the city of Barcelona, Spain.
Participation in the GHAGA awards implies full and complete acceptance of these T&Cs by each participant. Any statement to the contrary, such as not agreeing to the T&Cs, will result in the exclusion of the participant and, as a result, Grifols will be released from fulfilling any obligations with respect to said participants.
It is hereby acknowledged that none of the awards granted is conditioned upon any promotion, prescription and/or use of any products commercialized by Grifols nor it is intended to influence the awardees and the Institutions to do so.
Grifols reserves the right to cancel the GHAGA awards at any time on grounds of force majeure, lack of participation or for any other valid reason.
Grifols reserves the right to disqualify any participant who infringes any of the provisions regulated in these T&Cs and/or any applicable regulation.
Grifols reserves the right to modify these T&Cs in case any irregularity is detected that might influence the objectivity and transparency of the GHAGA awards.
Date of creation: July 2019
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?